Recruiting
A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart Failure
NCT07584967· Phase 2· AnaCardio AB· Source
Not yet recruiting
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
NCT07116473· Phase 3· Eidos Therapeutics, a BridgeBio company· Source
Not yet recruiting
Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
NCT07901868· Phase 2· PETHEMA Foundation· Source
Not yet recruiting
A Phase 3 Open-Label, Randomized Controlled Trial of T-bren (BL-M07D1) vs. Platinum-based Chemotherapy in Patients with HER2-expressing metastatic urothelial cancer with disease progression on or after anti-PD-(L)1-based therapy
2026-527617-29-00· Phase 3· Systimmune Inc.· Source
Recruiting
A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-OLE).
2026-526139-20-00· Phase 3· Kardigan Inc.· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
NCT07541170· Phase 3· Hoffmann-La Roche· Source
Not yet recruiting
Multicenter, open label, phase II clinical trial evaluating the combination of elranatamab with mezigdomide and dexamethasone in patients with relapsed/refractory multiple myeloma
2026-526352-31-00· Phase 2· Fundacion PETHEMA· Source
Recruiting
Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis
NCT07695701· Phase 4· Eidos Therapeutics, a BridgeBio company· Source
Active, not recruiting
A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small cell lung cancer.
2023-503298-39-00· Phase 3· AstraZeneca AB· Source
Recruiting
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)
2025-521587-35-00· Phase 3· Summit Therapeutics Inc.· Source
Recruiting
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
NCT07393282· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting
Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients
NCT07242547· Phase 2· Fundación GECP· Source
Recruiting
Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER)
NCT07611747· Phase 4· Instituto de Investigación Marqués de Valdecilla· Source
Recruiting
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
NCT07223814· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source
Recruiting
A Study of the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy.
2025-522553-19-00· Phase 2/3· Kardigan Inc.· Source
Recruiting
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
NCT07202546· Phase 2· ViiV Healthcare· Source
Recruiting
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
NCT07223203· Phase 3· Alnylam Pharmaceuticals· Source
Not yet recruiting
Phase 1b/2 Trial of OMTX705, an Anti-Fibroblast Activation Protein Antibody-Drug Conjugate, in Combination with Carboplatin, Pemetrexed and Tislelizumab in Patients with Advanced/Metastatic Non-squamous Non-Small Cell Lung Cancer
2025-521989-95-00· Phase 1/2· Oncomatryx Biopharma S.L.· Source
Recruiting
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
NCT06908304· Phase 3· Maia Biotechnology· Source
Recruiting
A randomized, double-blinded, placebo-controlled trial to evaluate the efficacy and safety of ninerafaxstat in patients with symptomatic non-obstructive hypertrophic cardiomyopathy
2024-515125-28-00· Phase 2· Imbria Pharmaceuticals Inc.· Source
Recruiting
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
NCT07207811· Phase 3· Novo Nordisk A/S· Source
Recruiting
A study to evaluate acalabrutinib, in combination with the R-CHOP standard of care, for previously untreated mantle cell lymphoma in Spain.
2025-521152-34-00· Phase 2· Astrazeneca Farmaceutica Spain S.A.· Source
Not yet recruiting
Exploring the Anti-ageing Effects of Metformin in COPD
NCT06999343· Phase 3· Fundación Instituto de Investigación Sanitaria de Navarra· Source
Recruiting
PALACE: Cemiplimab Trial According to ctDNA Levels
NCT06917573· Phase 2· Fundación GECP· Source
Recruiting
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401· Phase 3· Pfizer· Source
Active, not recruiting
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
NCT07053384· Phase 1· ViiV Healthcare· Source
Recruiting
Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)
NCT07153445· Phase 2· Fundación GECP· Source
Recruiting
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT07052903· Phase 3· Alnylam Pharmaceuticals· Source
Recruiting
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895· Phase 3· Eidos Therapeutics, a BridgeBio company· Source
Recruiting
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310· Phase 3· Mirati Therapeutics Inc.· Source
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
NCT06868277· Phase 3· AstraZeneca· Source
Recruiting
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
NCT06431633· Phase 3· Fundación GECP· Source
Recruiting
ANALYSIS OF EFFECTIVENESS OF NEOADJUVANT CHEMOTHERAPY IN THE TREATMENT OF LOCALLY ADVANCED COLON CANCER.
2024-519825-39-00· Phase 2· Clinica Universidad De Navarra· Source
Active, not recruiting
Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
NCT06668558· Phase 2· Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias· Source
Recruiting
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
NCT06472245· Phase 3· OSE Immunotherapeutics· Source
Active, not recruiting
A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Refractory Classical Hodgkin’s Lymphoma, Followed by Brentuximab Vedotin Consolidation (instead of Autologous Hematopoietic Stem Cell Transplantation) in Those who Attained a Metabolic Complete Remission after Salvage Therapy
NCT04378647· Phase 2· Fundacion Geltamo· Source
Recruiting
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) after immunotherapy failure.
2023-509340-10-00· Phase 3· OSE Immunotherapeutics· Source
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386· Phase 3· Bristol-Myers Squibb· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
NCT06481891· Phase 3· Lexicon Pharmaceuticals· Source
Active, not recruiting
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
NCT05979311· Phase 3· ViiV Healthcare· Source
Recruiting
Global Trial in APG2575 for Patients With CLL/SLL
NCT06104566· Phase 3· Ascentage Pharma Group Inc.· Source
Recruiting
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
NCT06128629· Phase 3· Intellia Therapeutics· Source
Active, not recruiting
Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes
NCT06282978· Phase 2· PETHEMA Foundation· Source
Active, not recruiting
An open label, multicenter, phase II study of Elranatamab as single agent for the treatment of relapsed or refractory myeloma in patients previously exposed to three-drug classes
2023-504273-21-00· Phase 2· Pethema Fundacion· Source
Recruiting
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05730036· Phase 3· Regeneron Pharmaceuticals· Source
Active, not recruiting
A Real-life Study of the Use of Cabotegravir Plus Rilpivirine Long-acting in ART-experienced Pre-treated People With HIV
NCT06518408· University Hospital Virgen de las Nieves· Source
Active, not recruiting
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.
NCT05527340· Phase 2· PETHEMA Foundation· Source
Recruiting
NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide
NCT05558319· Phase 3· PETHEMA Foundation· Source
Active, not recruiting
The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD
NCT05374291· Phase 3· University Medical Center Groningen· Source
Showing 50 of 77.